Cidara rises after EU approves fungal infection treatment

Cidara Therapeutics

22/12/2023 13:45

** Shares of therapy developer Cidara Therapeutics  CDTX.O 
rise 15.6% to 85 cents premarket
    ** Co says its fungal infection treatment Rezzayo has been
approved in the European Union for the treatment of invasive
candidiasis in adults
    ** Adds co is entitled to receive a milestone payment of
about $11.14 mln on approval from partner Mundipharma 
    ** Invasive candidiasis is an infection caused by a type of
fungus called Candida and can affect the blood, heart, brain and
other body parts
    ** Up to last close, stock down 2.4% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))